Tumor cell (recognized by allogeneic gamma delta T cells)

Tumor cells recognized by allogeneic gamma delta (γδ) T cells represent a cellular target population in oncology characterized by the expression of non-peptide stress antigens. Unlike conventional αβ T cells, γδ T cells identify these malignant cells independently of Major Histocompatibility Complex (MHC) restriction, primarily through the Vγ9Vδ2 T-cell receptor (TCR) and the NKG2D co-receptor (Nature Reviews Immunology, 2019). Key molecular targets on the tumor cell surface include Butyrophilin 3A1 (BTN3A1), which presents metabolic intermediates like isopentenyl pyrophosphate (IPP), and stress-induced proteins such as MICA and MICB (Frontiers in Immunology, 2020). Upon recognition, allogeneic γδ T cells exert potent anti-tumor activity by releasing perforins and granzymes and secreting pro-inflammatory cytokines like IFN-γ and TNF-α (Journal for ImmunoTherapy of Cancer, 2021). This target-effector relationship is the basis for several "off-the-shelf" cellular therapies currently in clinical development, which offer a reduced risk of Graft-versus-Host Disease (GvHD) compared to traditional T-cell products (Blood, 2018). Therapeutic strategies often employ aminobisphosphonates to sensitize tumor cells by inducing IPP accumulation, thereby enhancing γδ T-cell mediated lysis (Cancers, 2021).

Other names

Cancer cellMalignant cellNeoplastic cellTarget cell

MHC-independent recognition of stress-induced ligands (e.g., BTN3A1, MICA/B) by allogeneic gamma delta T cells, leading to direct cytotoxic lysis and cytokine production.